文献速递瓣膜外科

瓣膜手术中直视下植入无导线起搏器的可行性与安全性

Leadless pacemaker implantation under direct visualization during valve surgery.
PubMed 文献 · J Thorac Cardiovasc Surg · 2020-08-06

本研究回顾性分析了15例在瓣膜手术中直视下植入无导线起搏器的成人患者,主要起搏指征为病态窦房结综合征伴停搏、心房颤动伴缓慢心室率、完全性心脏传导阻滞及术后心脏传导阻滞高风险。结果显示93%患者体外循环后即刻起搏阈值正常,随访期间阻抗和感知值稳定,无手术并发症或器械故障,73%患者因此避免临时心表起搏导线。结论认为该杂交方法可行且安全,可能简化瓣膜手术患者的围术期管理。

要点

  • 瓣膜手术中直视下植入无导线起搏器可行且安全,无手术并发症或器械故障。
  • 93%患者体外循环后即刻起搏阈值正常(≤2.0 V at 0.24 ms),随访期间阻抗和感知稳定。
  • 73%患者因起搏器性能可靠而避免放置临时心表起搏导线。

核心结论

  • 瓣膜手术中直视下植入无导线起搏器可行且安全,可能简化有单腔起搏指征患者的围术期管理。

研究设计与样本

  • 回顾性分析连续15例在瓣膜手术时直视下植入无导线起搏器的成人患者。

主要发现

  • 患者年龄67.5 ± 17岁,6例(40%)为男性,14例(93%)有心房颤动。
  • 5例(33.3%)行孤立三尖瓣置换,其余行多瓣膜手术包括同期三尖瓣修复/置换。
  • 93%(14例)患者体外循环后即刻起搏阈值正常(≤2.0 V at 0.24 ms),余1例次晨正常。
  • 随访151 ± 119天期间所有患者阻抗/感知值正常且稳定。
  • 11例(73%)因起搏器性能可靠而避免临时心表起搏导线,无手术并发症或器械故障。

关键数值与推荐

  • 单腔起搏指征:病态窦房结综合征伴停搏(53.3%)、心房颤动伴缓慢心室率(13.3%)或完全性心脏传导阻滞(6.6%)、术后心脏传导阻滞高风险(26.6%)。

临床怎么用

  • 对于有单腔起搏指征的瓣膜手术患者,可考虑术中直视下植入无导线起搏器,可能减少临时心表起搏导线的使用。

局限性

  • 回顾性分析,样本量小(n=15),随访时间有限(151 ± 119天)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The leadless cardiac pacemaker is typically implanted percutaneously and has been widely used for patients who have already undergone valve surgery. We sought to determine the feasibility and safety of implanting the leadless pacemaker under direct visualization during valve surgery. METHODS: We performed a retrospective analysis of consecutive adult patients (n = 15) who underwent implantation of a leadless pacemaker under direct visualization at the time of valve surgery. Indications for single-chamber pacing were sick sinus syndrome with pauses (53.3%), atrial fibrillation with slow ventricular rates (13.3%) or complete heart block (6.6%), and elevated risk for postoperative heart block (26.6%). Leadless pacemaker performance and pacing percentage were assessed. RESULTS: Patients' age was 67.5 ± 17 years, 6 patients (40%) were male, and 14 patients (93%) had atrial fibrillation. Isolated tricuspid valve replacement was performed in 5 patients (33.3%), and the remainder underwent multivalve surgery that included concomitant tricuspid valve repair/replacement. In 93% of the patients (n = 14), the immediate post-cardiopulmonary bypass pacing thresholds were normal (≤2.0 V at 0.24 ms) and normalized in the remaining patient by the next morning. The impedance/sensing values were normal and stable through follow-up (151 ± 119 days) in all patients. Reliable leadless pacemaker performance allowed for deferral of temporary epicardial wires in 11 patients (73%). There were no procedural complications or device malfunction. CONCLUSIONS: Leadless cardiac pacemaker implantation during valve surgery is feasible and safe. This hybrid approach to pacing may simplify the perioperative management of patients undergoing valve surgery who have an indication for single-chamber pacing.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Shivamurthy P, Miller MA, El-Eshmawi A, et al. Leadless pacemaker implantation under direct visualization during valve surgery. J Thorac Cardiovasc Surg. 2020. PMID: 32891452. doi:10.1016/j.jtcvs.2020.07.092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。